Our mission is to bring hope to people living with cystic fibrosis.
Part of that mission is the inspiration and vision of hope to relieve their burden;
hope for an abundant life; hope for more tomorrows.

These voices are a part of that mission…

Two treatments daily – 
for 28 days –
for each participant

Dr. N. Simmonds

“As a potential treatment for the respiratory dysfunction of cystic fibrosis in all patients regardless of their genetic mutation, this study is of great interest to our patient population and we look forward to its successful completion,” said Nicholas Simmonds, consultant respiratory physician and associate director of the Adult CF Centre at the Royal Brompton Hospital in London and a principal investigator in the study.

Dr. Samantha Smythe

“The Clinical Trial Network was pleased to review this important protocol and to approve it for inclusion in the CTN with its highest priority rating,” said Dr. Tim Lee, Director of the Clinical Trials Network (CTN) of the European Cystic Fibrosis Society. “We look forward to working with Spyryx Biosciences to continue the development of this important potential treatment.”

Clinical Trial